OncoMatch/Clinical Trials/NCT05226494
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
Is NCT05226494 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies fb-PMT for glioma, malignant.
Treatment: fb-PMT — Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: surgery/biopsy
Prior completion of and recovery from the effects of standard of care for glioblastoma management with surgery/biopsy and radiotherapy
Must have received: radiotherapy
Prior completion of and recovery from the effects of standard of care for glioblastoma management with surgery/biopsy and radiotherapy
Cannot have received: bevacizumab (bevacizumab)
Use of bevacizumab or any other experimental drug or therapy within 28 days of study treatment
Cannot have received: experimental therapy
Use of bevacizumab or any other experimental drug or therapy within 28 days of study treatment
Cannot have received: fb-PMT or related drugs
Prior therapy with fb-PMT or related drugs
Lab requirements
Blood counts
Adequate bone marrow function, confirmed by laboratory testing at screening
Kidney function
Adequate organ function, confirmed by laboratory testing at screening
Liver function
Adequate organ function, confirmed by laboratory testing at screening
Adequate bone marrow and organ function, confirmed by laboratory testing at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Smilow Cancer Hospital · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify